Riordan Clinic Research Institute February 2013 The Riordan IVC Protocol for Adjunctive Cancer Care Intravenous Ascorbate as a Chemotherapeutic and Biological Response Modifying Agent 18 CONCLUSIONS Vitamin C can be safely administered by intravenous infusion at maximum doses of one-hundred grams or less, provided the precautions outlined in this report are taken. At these doses, peak plasma ascorbate concentrations can exceed 20 mM. There are several potential benefits to giving IVC to cancer patients that make it an ideal adjunctive care choice: • Cancer patients are often depleted of vitamin C, and IVC provides an efficient means of restoring tissue stores. • IVC has been shown to improve quality of life in cancer patients by a variety of metrics. • IVC reduces inflammation (as measured by c-reactive protein levels) and reduces the production of pro-inflammatory cytokines. • At high concentrations, ascorbate is preferentially toxic to tumor cells and is an angiogenesis inhibitor. The next key step in researching the use of IVC for cancer would be Phase II studies, some of which are currently underway. IVC may also have a variety of other applications, such as combating infections, treating rheumatoid arthritis, and treating ADHD and other mental illnesses where inflammation may play a role. REFERENCES Agus, D., Vera, J. & Golde, D., 1999. Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res., Volume 59, pp. 4555-8. Ashino, H. et al., 2003. Novel function of ascorbic acid as an angiostatic factor. Angiogenesis, Volume 6, pp. 259-69. Belin, S. et al., 2009. Antiproliferative effect of ascorbic acid is associated with inhibition of genes necessary to cell cycle progression. PLoS ONE, Volume 4, p. e4409. Benade, L., Howard, T. & Burk, D., 1969. Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4-triazole. Oncology, Volume 23, pp. 33-43. Berlin, S. et al., 2009. Antiproliferative effect of ascorbic acid is associated with inhibition of genes necessary for cell cycle progression. PLoS ONE, Volume 4, pp. E44-0. Block, K. et al., 2008. Impact of antioxidant supplementaion on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer, Volume 123, pp. 1227-39. Cameron, E. & Pauling, L., 1976. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. PNAS USA, Volume 73, pp. 3685-9. Riordan Clinic Research Institute February 2013 The Riordan IVC Protocol for Adjunctive Cancer Care Intravenous Ascorbate as a Chemotherapeutic and Biological Response Modifying Agent 19 Cameron, E., Pauling, L. & Leibovitz, B., 1979. Ascorbic acid and cancer, a review. Cancer Res, Volume 39, pp. 663-81. Campbell, A. & Jack, T., 1979. Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J, Volume 24, p. 151. Campbell, G., Steinberg, M. & Bower, J., 1975. Letter: ascorbic acid induced hemolysis in a G-6-PD deficiency.. Ann Intern Med, Volume 82, p. 810. Casciari, J., Riordan, H., Miranda-Massari, J. & Gonzalez, M., 2005. Effects of high dose of ascorbate administration on L-10 tumor growth in guinea pigs. PRHSJ, Volume 24, pp. 145-50. Casciari, J., Riordan, N. S. T. M. X., Jackson, J. & Riordan, H., 2001. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br. J. Cancer, Volume 84, pp. 1544-50. Chen, Q. et al., 2008. Pharmaologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. PNAS USA, Volume 105, pp. 11105-9. Chen, Q. et al., 2005. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. PNAS USA, Volume 205, pp. 13604-13609. Creagan, E. et al., 1979. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: A controlled trial. NEJM, Volume 301, pp. 687-690. Drisko, J., Chapman, J. & Hunter, V., 2003. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. Am J Coll Nutr, Volume 22, pp. 118-23. Du, J. et al., 2010. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res, Volume 16, pp. 509-20. Espey, M. et al., 2011. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med, Volume 50, pp. 1610-19. Espey, M., Chen, Q. & Levine, M., 2009. Comment re: vitamin C antagonizes the cytotoxic effects of chemotherapy. Cancer Research , Volume 69, p. 8830. Frei, B. & Lawson, S., 2008. Vitamin C and cancer revisited. PNAC USA, Volume 105, pp. 11037-8. Fromberg, A. et al., 2011. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells toward cytostatic drugs.. Cancer Chemother Pharmacol, Volume 67, pp. 1157-66. Fujita, K. et al., 1982. Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res, Volume 309-16, p. 42. Geeraert, L., 2012. CAM-Cancer Consortium. Intravenous high-dose vitamin C. [Online] Available at: Ginter, E., Bobeck, P. & Vargova, D., 1979. Tissue levels and optimal dosage of vitamin C in guinea pigs.. Nutr Metab, Volume 27, pp. 217-26. Gonzalez, M. et al., 2002. Inhibition of human breast cancer carcinoma cell proliferation by ascorbate and copper.. PRHSJ, Volume 21, pp. 21-3. Heaney, M. et al., 2008. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res., Volume 68, pp. 8031-8. Henson, D., Block, G. & Levine, M., 1991. Ascorbic acid: biological functions and relation to cancer. JNCI, Volume 83, pp. 547-50. Hoffer, L. et al., 208. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol, Volume 1969-74, p. 19. Hoffman, F., 1985. Micronutrient requirements of cancer patients.. Cancer, 55(Supl. 1), pp. 145-50. Hornig, D., 1975. Distribution of ascorbic acid metabolites and analogues in man and animals. Ann NY Acad Sci, Volume 258, pp. 103-18. Jackson, J. & Hunninghake, R., 2006. False positive blood glucose readings after high-dose intravenous vitamin C. J Ortho Med, Volume 21, pp. 188-90. Riordan Clinic Research Institute February 2013 The Riordan IVC Protocol for Adjunctive Cancer Care Intravenous Ascorbate as a Chemotherapeutic and Biological Response Modifying Agent 20 Jackson, J., Riordan, H., Hunninghauke, R. & Riordan, N., 1995. High dose intravenous vitamin C and long time survival of a patient with cancer of the head and pancreas. J Ortho Med, Volume 10, pp. 87-8. Keith, M. & Pelletier, O., 1974. Ascorbic acid concentrations in leukocytes and selected organs of guinea pigs in response to increasing ascorbic acid intake. Am J Clin Nutr, Volume 27, pp. 368-72. Kuether, C., Telford, I. & Roe, J., 1988. The relation of the blood level of ascorbic acid to tissue concentrations of this vitamin and the histology of the incisor teeth in the guinea pig. J Nutrition, Volume 28, pp. 347-58. Kurbacher, C. et al., 1996. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett, Volume 103, pp. 183-9. Levine, M. et al., 1996. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. PNAS USA, Volume 93, pp. 3704-9. Lin, A., Chen, K., Chung, H. & Chang, S., 2010. The significance of plasma c-reactive protein in patients with elevated serum prostate-specific antigen levels. Urological Sci, Volume 21, pp. 88-92. Mayland, C., Bennett, M. & Allan, K., 2005. Vitamin C deficiency in cancer patients. Palliat Med, Volume 19, pp. 17-20. McCormick, W., 1959. Cancer: a collagen disease, secondary to nutrition deficiency. Arch. Pediatr., Volume 76, pp. 166-171. Mikirova, N., Casciari, J. & Riordan, N., 2012. Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenesis Res, Volume 2, pp. 2-6. Mikirova, N., Casciari, J., Taylor, P. & Rogers, A., 2012. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Trans Med, Volume 10, pp. 189-99. Mikirova, N., Ichim, T. & Riordan, N., 2008. Anti-angiogenic effect of high doses of ascorbic acid.. J Transl Med, Volume 6, p. 50. Mikirova, N., Rogers, A., Casciari, J. & Taylor, P., 2012. Effects of high dose intravenous ascorbic acid on the level of inflammation in patients with rheumatoid arthritis. Mod Res Inflamm, Volume 1, pp. 26- 32. Moertel, C. et al., 1985. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have no prior chemotherapy: a randomized double-blind comparison.. NEJM, Volume 312, pp. 137-41. Monti, D. et al., 2012. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One, Volume 7, p. e29794. Murata, A., Morishige, F. & Yamaguchi, H., 1982. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Res Suppl, Volume 23, pp. 103-13. Okunieff, P. & Suit, H., 1987. Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine firbosarcomas. JNCI, Volume 79, pp. 377-81. Padayatti, S. et al., 2006. Intravenous vitamin C as a cancer therapy: three cases. CMAJ, Volume 174, pp. 937-42. Padayatty, S. & Levine, M., 2000. Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr., Volume 19, pp. 423-5. Padayatty, S. et al., 2010. Vitamin C: intravenous use by complementary and alternative medical practitioners and adverse effects. PLoS ONE, Volume 5, p. 11414. Padayatty, S. et al., 2004. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann. Intern. Med., Volume 140, pp. 533-37. Page, E. et al., 2007. Hypoxia incudible factor-1 (alpha) stabilization in nonhypoxic conditions: role of oxidation and intracellualr ascorbate depletion. Mol Biol Cell, Volume 19, p